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Abstract:  
Chronic inflammatory neuropathies represent a heterogeneous group of disorders 
which affect patients’ functional status and quality of life. We conducted a systematic 
review of the scientific literature on the effects of both disease and treatment 
interventions on health-related quality of life (HRQoL) in this patient population. The 
available data are limited, as few studies have systematically considered HRQoL in 
patients with inflammatory neuropathies. Moreover, in treatment trials, HRQoL 
measures have exclusively been used as secondary outcome measures. There is some 
evidence suggesting that baseline pre-treatment HRQoL reports are lower in patients 
with chronic inflammatory neuropathy than in age and gender-matched controls. 
Following treatment interventions, improvements in self-reported measures were 
consistently documented in the physical domain of HRQoL, which in turn correlated 
with improvements in traditional strength and functional scales. The impact of 
available treatments on the quality of life of patients with inflammatory neuropathies 
remains largely under-investigated. Interestingly, recent, although limited evidence 
from generic HRQoL measures may partly or completely contradict the results found 
with the primary, traditional outcome measures used (rituximab for anti-MAG 
neuropathy; immunoglobulins versus corticosteroids for chronic inflammatory 
demyelinating polyneuropathy). Similarly, HRQoL measures may suggest superiority, 
rather than equivalence, of certain drug administration methods (subcutaneous over 
intravenous immunoglobulins). Further research is needed to assess HR-QOL in 
patients with untreated chronic inflammatory neuropathies in comparison to 
normative values, as well as precisely quantify treatment benefit. The role of both 
generic and disease-specific HRQoL measures in the evaluation of patients with 
chronic inflammatory neuropathies is also worthy of further consideration. 
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Introduction. 
 
Health-related Quality of Life (HRQoL) is a concept that reflects subjective 
individual perceptions of the effects of an illness and its treatment on physical, mental 
and social aspects of life [1]. As a result, HRQoL appears to be directly indicative of 
reduced level of patients’ well-being from their disease. Changes may otherwise 
indicate genuine and meaningful effects of treatments administered. Therefore, use of 
HRQoL scales has been proposed as an appropriate method to ascertain actual effects 
on patients’ lives, resulting from disease as well as from therapeutic interventions, and 
should at least complement other health status measurements in neuromuscular 
conditions. Although an earlier study, which will be detailed as part of the current 
review, had demonstrated the Medical Outcome Study 36-item short form health 
status scale (SF-36) Questionnaire as a potentially valuable instrument in 
inflammatory neuropathies [2], the extent to which HRQoL evaluations have been 
used subsequently in the research setting has appeared variable. 
 
Chronic inflammatory neuropathies are a broad and heterogeneous group of 
conditions manifesting in focal, multifocal or generalized sensory and/or motor 
deficits, evolving in a progressive or relapsing and remitting manner. In chronic 
inflammatory neuropathies, different therapies have demonstrated favourable effects 
on muscle strength and/or neurological function. How relevant these can be in 
actually improving the day-to-day living of treated patients may however be difficult 
to ascertain. Furthermore, baseline pre-treatment quality of life characteristics are 
uncertain in this group of disorders and how that may compare with normative values 
is unknown. We conducted a systematic review of the literature relating to use of 
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instruments measuring HRQoL in chronic inflammatory neuropathy, focusing in 
particular on chronic inflammatory demyelinating polyneuropathy (CIDP) and 
multifocal motor neuropathy (MMN). We aimed to specifically analyze the use of 
HRQoL measures in the studied populations, in relation to baseline function as well as 
therapeutic benefit and its clinical correlates. 
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Materials and Methods. 
 
Our search methodology followed the standard guidelines for systematic literature 
reviews outlined in the PRISMA statement [3]. We conducted a Medline search of all 
English language articles published between 1966-October 2014 on HRQoL in all 
forms of chronic inflammatory neuropathies. We used Medline with the search MeSH 
terms “inflammatory neuropathy”, as well as “chronic neuropathy”, 
“paraproteinaemic demyelinating neuropathy” (“PDN”), “POEMS” 
(“Polyneuropathy, Organomegaly, Endocrinopathy, M-Protein, Skin”) syndrome, 
“CANOMAD” (“Chronic Ataxic Neuropathy with Ophthalmoplegia, M-protein and 
Disialosyl antibodies”) syndrome, each combined with “Quality of Life” and “Health 
Status”. Reference lists of each retrieved paper were screened for additional relevant 
publications. All papers discussing specifically ascertainment of HRQoL in any 
aspect of baseline clinical manifestations, treatment effects or disease monitoring, 
were analyzed. Articles were included irrespective of disease subtype or course, 
number of patients studied, main purpose of the analysis considered, type of 
monitoring otherwise performed/described in addition to HRQoL, or type of 
therapeutic intervention utilized. Papers considered were read in full-text version and 
analyzed in detail in relation to HRQoL evaluations, results and conclusions. 
Reference lists of retrieved articles were searched for any additional relevant 
publications in the field. The findings are presented here in a descriptive manner 
following the chronological development of this rapidly expanding field.  
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Results. 
 
We retrieved a total of 23 articles which had descriptions of use of instruments 
measuring HRQoL in patients diagnosed with chronic inflammatory neuropathy. The 
reviewed articles, summarized in Table 1. showed heterogeneity in terms of study 
focus. Some studies described the results of a cross-sectional analysis of HRQoL in 
patients with CIDP. In other studies, changes in HRQoL were described as part of a 
therapeutic intervention for CIDP or MMN, with intravenous immunoglobulin (IVIg) 
treatment versus corticosteroids/placebo, or subcutaneous immunoglobulin (SCIg) 
versus IVIg/placebo, as a secondary outcome measure. In few studies, HRQoL was 
evaluated as part of the IVIg-related benefit in small treated cohorts, outside the 
setting of a drug trial. Finally in a single recent study, HRQoL was used as secondary 
outcome measure in a trial setting of rituximab versus placebo for anti-myelin 
associated glycoprotein (MAG) antibody neuropathy. 
 
The first relevant study was published in 2001 and presented the results of a 
multicentre double-blind cross-over randomized controlled trial (RCT) of IVIg versus 
oral corticosteroids, in 25 patients with chronic inflammatory neuropathy [4]. Both 
treatments provided significant, but not significantly different, improvements at 2 
weeks in the primary outcome measure, the 11-point Inflammatory Neuropathy Cause 
and Treatment (INCAT) scale. The study participants also completed the SF-36, a 
generic HRQoL questionnaire consisting of 36 items encompassing the domains of 
physical functioning (10 items), role functioning-physical (4 items), role functioning-
emotional (3 items), social functioning (2 items), body pain (2 items), mental health 
(5 items), vitality (4 items), general health perception (5 items), and change in health, 
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which is scored separately. In this study there were no significant changes of HRQoL 
according to the SF-36 physical functioning scores after 6 weeks in either treatment 
group. In a separate publication [5], the authors detailed the results of their 
assessments using the EuroQol (EQ)-5D instrument to ascertain the broader impact of 
the two interventions. The EQ-5D is a shorter generic HRQoL measure consisting of 
5 domains (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression), each of which has three levels of severity (1, no problem; 2, 
some problem and 3, serious problem). As opposed to the findings of treatment 
equivalence for the primary outcome measure, the EQ-5D was unchanged for the 
prednisolone group, whilst there was a relatively large improvement in quality of life 
for the IVIg group. Treatment with IVIg resulted in a consistent, albeit non-
significant, improvement in quality of life compared with prednisolone. 
 
Merkies et al. used the SF-36 and other measures including the Medical Research 
Council sum score, sensory sum score, INCAT score and Hughes functional scale, to 
assess 23 stable patients with CIDP and 8 with paraproteinaemic demyelinating 
neuropathy (PDN) [2]. In addition they performed serial evaluations as part of an 
open-label 1-year longitudinal study, in 13 of the patients with CIDP. The reported 
mean SF-36 domain scores and summary values for a random, nationwide sample of 
1,742 healthy individuals in the Netherlands were used as comparator. In the stable 
group, mean SF-36 subscales and summary scores (Physical Component Score: PCS; 
and Mental Component Score; MCS) were compared with the reported mean normal 
values for the Dutch population. Correlations were ascertained with various other 
scales used and the impact of age and duration of symptoms was also determined. In 
the longitudinally examined patients, mean SF-36 subscale and summary scores were 
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analysed and compared at various arbitrarily chosen follow-up points (weeks 0, 26, 
52) with the reported SF-36 normative Dutch data. The mean SF-36 subscale scores 
with corresponding mean PCS and MCS scores for the stable group were found to be 
significantly lower compared with the mean normal values, although this included a 
large group of 83 patients with Guillain-Barré (GBS) syndrome. Precise breakdown 
data for CIDP and PDN were not provided. In the longitudinal study, all patients 
demonstrated a general increase in HRQoL at follow-up. The SF-36 adequately 
captured improvement in these patients, demonstrating a gradual shift of all scores 
towards normal values in the whole group. At entry, all dimensions and summary 
measures were substantially lower compared with the corresponding normal values. 
All SF-36 components, except for the “physical functioning” and “role functioning-
physical” domains, as well as PCS score, reached normal values at 6 and 12 months 
of follow-up. Interestingly, the statistical analysis showed that general strength only 
explained 12% and sensory functions only 16%, of the SF-36 physical summary 
scores. Otherwise, no significant association was obtained between weakness and 
sensory deficit and SF-36 mental summary scores. The authors concluded that the SF-
36 could be considered as an adjunct outcome measure for future studies, 
complementing traditional strength and sensory scales. In addition, they indicated that 
variables such as depression and fatigue may, as previously suggested, represent 
potential contributors to decrement in HRQoL. 
 
In a heterogeneous population consisting of 8 patients with CIDP and 3 with MMN, 
but also 3 with GBS and 10 with myasthenia gravis, improvements of the Italian 
version of the SF-36 were reported after IVIg therapy [6, 7]. Analysis of changes in 
SF-36 subscores indicated highly significant differences of vitality, physical role, and 
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physical function subscores from normal, which all improved after IVIg therapy. On 
the other hand, the comparison of mental scores between the baseline evaluation and 
the follow-up evaluation revealed no differences, leading the authors to conclude that 
IVIg did not improve psychological distress. The lack of data regarding the exact 
breakdown of different diseases makes it difficult to reach any further conclusions 
from these two papers. However it is likely that the expected major post-IVIg 
improvements in patients severely disabled in the acute stages of GBS and myasthenic 
crises could have biased the results. 
 
In a study of physical training, a 12-week bicycle exercise programme was 
implemented in 16 patients with GBS with relatively good recovery and 4 with stable 
CIDP [8]. All were severely fatigued.  Besides the Fatigue Severity Score (FSS), 
Fatigue Impact Scale (FIS), GBS disability score, Hospital Anxiety and Depression 
Scale (HAD), Rotterdam Handicap Scale (RHS), the SF-36 was also utilized. 
Significant improvements from baseline were obtained for FSS, FIS, HAD and RHS 
for the whole cohort. The PCS, but not the MCS, of the SF-36 improved significantly 
(p<0.05). Interestingly, in comparison with healthy controls, only PCS were 
significantly different to baseline in patients, whereas MCS were comparable, 
although still improved with the intervention. Unfortunately, precise breakdown of 
results for the SF-36 was not provided in relation to CIDP patients specifically. 
 
The ICE Trial, a randomized, double-blind, response-conditional crossover study of 
immune globulin IV, 10% caprylate/chromatography purified (IGIV-C 
[Gamunex®]) versus placebo was published in 2008 [9]. This was a multicentre 
international study involving 117 patients recruited across 33 centres. During the first 
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period, 32/59 (54%) patients treated with IGIV-C and 12/58 (21%) patients who 
received placebo had an improvement in adjusted INCAT disability score that was 
maintained through to week 24 (p=0·0002). Significant improvements from baseline 
to endpoint were also recorded for grip strength in both dominant and non-dominant 
hands. Results were similar during the crossover period. During the extension phase 
of the study, participants who continued to receive IGIV-C had a significantly longer 
time to relapse than patients treated with placebo. This study used HRQoL 
evaluations as secondary outcome measure, and the results were published separately 
in two additional papers [10, 11]. The SF-36 Questionnaire was administered at 
baseline and at each study endpoint. The lowest scores for SF-36 domains at baseline 
were in role-physical and physical functioning in both the IGIV-C and placebo 
groups. Treatment with IGIV-C significantly improved the physical component 
summary score of the SF-36 from baseline compared with placebo. Larger 
improvements from baseline were observed across all domains in patients treated with 
IGIV-C than with the placebo group, with differences in physical functioning, role-
physical, social functioning, and mental health domains achieving statistical 
significance. During the cross-over period, treatment with IGIV-C significantly 
improved the physical component summary score of the SF-36 from baseline 
compared with placebo to a similar degree as seen during the first period. Larger 
improvements from baseline in all domains were observed with IGIV-C versus 
placebo, with physical functioning, bodily pain, and social functioning all reaching 
significance. Mean improvements in SF-36 scores reported during the first period or 
the crossover period were maintained or even amplified in the extension period by the 
participants who continued treatment with IGIV-C. However, general decrease in SF-
36 scores was observed in participants re-randomized to the placebo group. 
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Additionally the authors carried out a detailed analysis and interpretation of the 
effects of CIDP in terms of HR-QoL-related impairments to activity and participation 
restrictions, using correlates with the SF-36 [11]. At baseline, PCS correlated highly 
with MRC sum score, grip strength of both dominant and non-dominant hand, INCAT 
disability score and Rotterdam handicap scale. The MCS on the other hand failed to 
correlate at baseline with any strength or functional parameter, but showed a degree of 
association with electrophysiological proximal motor conduction block, which is of 
uncertain significance. However, interestingly, change from baseline demonstrated on 
univariate analysis at end point showed that changes in MCS as well as PCS were 
significantly associated to changes in INCAT disability score, INCAT sensory sum 
score and MRC sum score. A number of associations with electrophysiological 
parameters were also ascertained, including averaged motor amplitude and degree of 
conduction block, although the practical relevance of these findings appears, again, 
uncertain. 
 
Harbo et al. performed a cross-sectional study on 14 patients with CIDP using 
isokinetic strength, muscle strength as evaluated clinically, neurological symptom 
score, Overall Disability Sum Score, 10-metre walk and 40-metre walk, as well as the 
physical components of the validated Danish version of the SF-36 [12]. After 
correction for multiple comparisons, there was a significant impairment in patients 
with CIDP compared to healthy controls on the physical function and vitality scales, 
but interestingly not for role physical, bodily pain, general health perception, social 
functioning, role emotional, or mental health. The PCS was reduced in patients with 
CIDP, whereas the MCS was similar to that of healthy controls. The PCS, but not the 
MCS, correlated significantly with isokinetic strength. In relation to global HRQoL 
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findings in this cross-sectional analysis, the authors felt that their results may have 
been influenced by the social and cultural context, including the high standards of 
social care provision in Denmark, and concluded that their findings may, as a result, 
not be applicable to all CIDP cohorts. 
 
In another analysis, Harbo et al. evaluated the acute motor response following a single 
IVIg treatment course in 11 patients with CIDP [13]. Various assessment tools were 
used, including isokinetic strength, NIS (neuropathy impairment score)-strength 
score, functional tests such as the nine-hole peg test and 40-metre walk test, and in 
addition, the SF-36 Questionnaire. During the immunoglobulin treatment withdrawal 
period, significant correlations were ascertained between change in the combined 
isometric performance score and change in NIS-strength score and 40-metre walk test. 
However no correlations with SF-36 subscales were reported. Following 
immunoglobulin treatment, the increase in isometric strength was significant at day 5 
and progressed between days 5 and 10 without further increase at day 15. The clinical 
NIS-strength score improved at day 5 without further improvements. The physical 
subscales of SF-36 (physical function and role physical function) increased 
significantly at assessment on day 15, whereas the pain, social, emotional, and mental 
categories were unchanged. 
 
More recently, few trials of subcutaneous immunoglobulin therapy (SCIg) have been 
conducted in chronic inflammatory neuropathies and have used HRQoL measures as 
secondary outcome measures. In a single-blind randomized cross-over trial, 9 patients 
with MMN on regular IVIg treatment were recruited and randomized to receive either 
IVIg or SCIg and then crossed over to the other treatment [14]. The primary outcome 
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was the combined dynamometric strength score expressed relative to normal strength 
in 5-6 affected muscle groups at three joints and at hand grip. Functional scales were 
utilized as secondary outcomes. In addition, HRQoL was assessed using a validated 
Danish version of the SF-36 questionnaire. The items were summarized for PCS and 
MCS. The treatment methods were found to be equally effective with regard to the 
primary outcome, and, functionally, there were no significant performance differences 
for the nine-hole peg test or the 10-metre walk between S Ig and IVIg treatment 
arms. No differences were otherwise ascertained between the two treatments with 
regard to SF-36 PCS and MCS scores. In another, prospective, single-centre, open-
label interventional study from the Netherlands, 10 patients with MMN were switched 
from IVIg to SCIg at 50% or 100% of the previous intravenous dose [15]. Results 
showed that the primary outcome measure, the MRC sum score, was unchanged at 
equivalent doses of treatment, and that HRQoL assessment carried out using the SF-
36 Questionnaire showed no differences between IVIg and SCIg. In a further, open-
label, proof-of-concept multicentre study, 8 patients with MMN were switched from 
IVIg to SCIg, with primary outcome measure being muscle strength at 24 weeks [16]. 
Disability and HRQoL were also assessed using another scale, the Life Quality Index 
(LQI) along with a visual analogue scale (VAS) to evaluate health status. The LQI is a 
14-item self-reported questionnaire which provides scores on 4 major dimensions of 
patients’ perceptions on daily activities and satisfaction with medication: 
effectiveness, side effects, convenience and global satisfaction are rated on a 0-100 
scale (0 = not satisfied; 100 = fully satisfied). Scoring is arranged so that the more 
positive side of the pair gains highest scores. The LQI improved on SCIg in 6/8 
patients and VAS remained stable or improved in 7/8. No details of scores and 
comparisons of these with normative data were provided. In another prospective 
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longitudinal study from Italy, Cocito et al. demonstrated in 5 CIDP patients 
previously on IVIg, equivalence of SCIg on the primary end-points which consisted 
of MRC scores, ONLS (Overall Neuropathy Limitation Score), Grip strength and 
sensory sum score, as well as, for secondary outcomes, the SF-36 PCS and MCS and 
Modified LQI [17]. The same authors later reported significant quality of life 
improvements in 10 patients with CIDP, as measured by the LQI with use of 20% 
SCIg versus 16% SCIg which had allowed reduction in infusion rate [18]. In a single 
study specifically focusing on quality of life from the U.K., the SF-36 and LQI were 
used in 16 patients with MMN treated with either SCIg or IVIg [19]. Overall the mean 
LQI score for the SCIg group was higher than the IVIg group but this did not reach a 
significant difference (p=0.06). All individual mean item scores were higher in the 
SCIg group except for the item related to pain, where the SCIg was rated as causing 
more pain than IVIg. For the SF-36, overall the IVIg patient group had a lower, 
although non-significant, total score than the SCIg patient group (p=0.22). A 
significant difference was observed between IVIg patient group and SCIg patient 
group on the MCS (p=0.03), however no significant difference was observed on the 
PCS (p=0.38), although this was higher for the SCIg group. Of the 8 domains, a 
significant difference favouring SCIg was only observed for the vitality component 
(p=0004). Disease duration was the only factor found to significantly correlate with 
lower SF-36 (p=0.02), PCS (p=0.03), MCS (p=0.02) and for the specific dimensions 
of physical function (p=0.02), general health (p=0.003), social function (p=0.02) and 
vitality (p=0.02). Social class, work status, age, gender, and travel time to treatment 
centre were found not to be confounding factors. 
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In the most recent RCT for CIDP from the Italian group, IVIg treatment was 
compared to intravenous pulsed corticosteroids, using the difference in the proportion 
of patients discontinuing treatment with IVIg or intravenous methylprednisolone 
during the 6 months of therapy because of side-effects, intolerance, or inefficacy 
(defined as the absence of improvement after 2 months or worsening after 15 days) as 
primary outcome [20]. The results showed that more patients stopped 
methylprednisolone (11/21) than IVIg (3/24). This result was highly significant 
(p=0·0085). When adjusted for sex, age, disease duration, comorbidity, modified 
Rankin scale and ONLS scores at enrolment, as well as previous treatment with IVIg 
and steroids, the difference between the two groups remained significant (p=0·007). 
Reasons for discontinuation were lack of efficacy (8 in the steroid group vs. 3 in the 
IVIg group), adverse events (1 in the steroid group), or voluntary withdrawal (2 in the 
steroid group). Despite these results in favour of IVIg, SF-36 ratings revealed an 
improvement of 16.7 points at 6 months with steroids (p=0.0008) and of 14.2 points 
with IVIg (p=0.011), with no significant difference comparing the two treatment arms 
(p=0.3634), this result contrasting with the previous comparative analysis performed 
[1]. 
 
A recent cross-sectional analysis from the south-east of England, U.K., studied 
specifically HRQoL using the EQ-5D instrument, which was completed by 43/50 of 
patients with CIDP, 26/37 of patients with PDN and 9/19 of patients with MMN to 
whom it was sent [21]. In all three diseases, limitations in ability to self-care or carry 
out daily activities and pain were reported in at least 75% of cases. Anxiety and/or 
depression affected nearly 50% of patients. Difficulty with mobility was experienced 
in 83% of patients with CIDP, 81% of patients with PDN and 38% of patients with 
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MMN. Combining data from the three diseases, the utility scores were not 
significantly related to gender, age, disease duration or, interestingly, IVIg treatment. 
The mean utility scores of each of the three diseases were lower than the U.K. 
average, but higher than the scores obtained from a cohort of 737 patients with 
multiple sclerosis and from a cohort of 97 patients with Parkinson’s disease from the 
same country. In keeping with correlations described in other studies with 
neurological function, HRQoL was significantly higher in patients who were 
independently mobile or had no upper limb disability. 
 
A Canadian study specifically analysed the relationship between social support and 
quality of life, as assessed by a disease-specific HR-QoL scale, the Peripheral 
Neuropathy Quality of Life Instrument-97, in a population of 154 patients with 
neuropathy, amongst whom 31.9% had diabetic polyneuropathy, 16% CIDP and 9% 
PDN, most having [22]. Comparison of quality of life between the patients with 
neuropathy and a Canadian normative sample showed highly significantly lower 
scores for all eight SF-36 domains in patients with CIDP (p<0.001). Physical and 
psychological quality of life were related to pain and to autonomic symptoms. Social 
support was otherwise associated with psychological aspects of quality of life when 
adjusting for other factors. Male gender and severity of neuropathy were independent 
predictors of impairment in physical health dimensions of quality of life. As 
acknowledged by the authors,  major limitations for this study were the clinical 
heterogeneity of the neuropathic population and the absence of detailed findings for 
patients with CIDP and PDN. 
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Another recent cross-sectional study from Brazil specifically focused on the mini-
mental status examination (MMSE) and SF-36 scores in a cohort of CIDP patients 
[23]. The results were unfortunately not adequately detailed for meaningful 
conclusions. Although scores for various domains were provided, normative values 
for the relevant Brazilian population were not available for analysis. Comparisons 
were made with data from Denmark [13], although, as acknowledged by the authors, 
these comparisons were likely to be biased cultural differences. 
 
HRQoL measures have only been used rarely in studies of chronic inflammatory 
neuropathies other than CIDP. In a RCT of cyclophosphamide with prednisolone for 
polyneuropathy with IgM monoclonal gammopathy involving 35 patients stratified on 
the basis of their anti-MAG status, the SF-36 was used as a secondary outcome 
measure [24], with the Revised Rivermead Mobility Index used as primary outcome. 
Interestingly, although no effect could be demonstrated on the primary outcome, the 
MRC sum score, the sensory sum score and the SF-36 scores significantly improved 
in the first study phase of 6 months. The SF-36 itself improved by 31 points in 
treatment group vs. 5 points in placebo group (p=0.03). Similarly, in the latest 
placebo-controlled RCT of rituximab for anti-myelin-associated-glycoprotein (anti-
MAG) neuropathy [25], no effect could be demonstrated for the primary outcome 
measure, the INCAT sensory score at 12 months. Although improvement of the SF-36 
PCS, utilized as secondary outcome, only approached significance in favour of 
rituximab (p=0.08), subscores for physical functioning and role emotional improved 
significantly with the drug versus placebo (p=0.0069 and p=0.02, respectively). Of 
note, improvement of subscores for mental health, social functioning and bodily pain 
also approached statistical significance (p=0.08, p=0.07 and p=0.09, respectively). 
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Discussion. 
 
This review aimed to analyze the use of measures of HRQoL in all forms of published 
research in relation to chronic inflammatory neuropathies. The first striking finding is 
the relative scarcity of literature on this topic. This made further analysis of the data 
gathered, in addition to the purely descriptive one we have attempted to perform here, 
unfortunately unfeasible. Furthermore, variable use of scales, absence of normative 
values, and lack of longitudinal data, all represent major drawbacks in studies that 
have used HRQoL in their assessments of patients with chronic inflammatory 
neuropathies. 
 
The SF-36 appears to be a useful generic instrument to evaluate HRQoL adequately in 
CIDP and PDN [2], as shown by its performance across the studies analyzed in this 
review. Although the SF-36 was the most popular, other non-validated scales have 
also been used in the studies considered in our review. The results with these scales 
are however clearly more difficult to interpret. With the SF-36 itself, absence of age-
dependent reference values specific to the clinical population under study can  
make interpretation and meaningful inter-study comparisons impossible. Exclusive 
mention of aggregate PCS or MCS without the detailed breakdown also represents a 
limitation in some studies. 
 
The studies we have considered show that patients with CIDP in particular 
demonstrate lower baseline HRQoL measures, especially with regard to the physical 
component. However, from the limited available data, the degree of impairment may 
be lesser than in other neurological disorders and other HR-QOL domains such as 
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pain and general health perception, social functioning and mental health appear to be 
relatively spared. It cannot be ruled out that this finding reflects the fact that the 
reviewed studies were carried out in countries with high standards of healthcare and 
ready access to a wide range of currently available pharmacological and non-
pharmacological therapies. Improvement of the physical component of HRQoL 
otherwise appears to consistently occur with effective therapies such as IVIg, SCIg or 
steroids.  
 
One important finding of this review relates to the comparative therapeutic studies. 
Although it appeared possible that IVIg may offers a better option than steroids for 
patients with CIDP on the basis of short-term HRQoL data [1], this was not confirmed 
with the 6-month data from the latest comparative study [20]. In the economic context 
of the high costs of IVIg, this latter result, not consistent with the main study findings 
on the primary outcome, may raise important questions on the appropriateness of 
choice of first-line therapy for CIDP. Interestingly, in keeping with these findings, the 
recent cross-sectional U.K. study equally raises the issue of utility of long-term 
immunoglobulin therapy which, surprisingly, was not found to influence HRQoL 
[21]. Likewise, SCIg could be of actual greater benefit than IVIg for CIDP and MMN, 
from a broader HRQoL perspective, from specific standpoints such as the 
psychological component, the importance of which cannot be discounted when 
treating disabling diseases. Correlations of HRQoL measures were otherwise 
consistently found at baseline with strength scores, isokinetic strength and functional 
scores in CIDP. Longitudinally, changes in HRQoL also correlated with changes in 
these scales, interestingly including changes in the psychological domain in the 
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largest study performed to date [11]. This would appear to confirm the applicability 
and suitability of HRQoL measures and the SF-36 in particular in this setting. 
In therapeutic studies for CIDP, the HRQoL findings suggest that these measures, 
while correlating closely to traditional scales, may in addition provide useful 
information, not captured by these. The improvement of the MCS on active therapy in 
the ICE study demonstrates this [11]. The SCIg versus IVIg trials also revealed 
improved HRQoL for the former, while other scales showed equivalence. Similarly, 
the latest placebo-controlled trial of rituximab for anti-MAG neuropathy shows a 
similar positive impact of the active drug on several components of the HRQoL 
measures [25]. The results may have been also significant globally on the SF-36, with 
a greater sample size, contrasting again with the results for the primary outcome for 
this study. 
 
In conclusion, this review indicates that despite the limited data, HRQoL measures 
may be a useful clinical tool and represent a potentially important component of the 
assessment of patients with chronic inflammatory neuropathies. Disease-specific 
Rasch-built Overall Disability Scales (R-ODS) have become the preferred and most 
popular recently proposed assessment tool for inflammatory neuropathies [26] and 
appear to have superseded consideration of HRQoL scales in recent literature. 
Comparison of the suitability of traditional disability scales such as the INCAT Scale 
or ONLS, the R-ODS and HRQoL scales such as the SF-36 in the assessment and 
monitoring of clinically different entities such as CIDP, MMN and PDN, is not 
straight forward. As such, it is possible that use of HRQoL issues may be of greater 
relevance in conditions where clinically-relevant measurable changes are more 
difficult to predict or elicit. Conversely, in disorders where functional changes are of 
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large magnitude and more easily quantifiable, the relevance HRQoL measures may be 
may be more apparent in specific contexts, e.g. when making therapeutic decisions. 
However, use of a homogeneous validated scale such as the SF-36 may remain 
generally desirable and appears invaluable in capturing subjective aspects of baseline 
clinical presentations, as well as allow comparative analyses with other patient 
populations/healthy controls and contribute in determining meaningful treatment 
effects. Over the last few years, disease-specific HRQoL instruments have also been 
developed and validated for use in a number of common neurological conditions, 
ranging from multiple sclerosis (e.g. MSQOL-54 [27]) to epilepsy (e.g. QOLIE-10 
[28]) and movement disorders (e.g. PDQ-39 [29], PSP-QOL [30], GTS-QOL [31]). 
Specifically for neuropathy, a HRQoL instrument was developed using the SF-36 as 
framework [32]. However this 97-item tool has not been used in subsequent studies in 
chronic inflammatory neuropathies, with the exception of the wider Canadian study 
described in this review [22]. Its reappraisal for this subset of neuropathic disorders 
may prove to be helpful in dissecting the selective impact on different HR-QoL 
domains. Although these disease-specific psychometric tools do not allow 
comparisons between quality of life in the target condition and other disorders or 
healthy state, they often capture aspects of HRQoL which are important to particular 
patient populations and can be overlooked or underestimated when using generic 
instruments. The development of a disease-specific HRQoL instrument for patients 
with chronic inflammatory neuropathies, alongside the recently developed R-ODS 
scales, might likewise allow a more comprehensive assessment of the impact of the 
condition and its treatment on patients’ wellbeing. In general, further prospective 
studies are needed to ascertain the exact place and potential future role of HRQoL 
measures in chronic inflammatory neuropathies. Although limited, current available 
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data are of great interest as we believe this review highlights, and raise many 
questions, including that of the right choices for the primary outcome measures for 
future therapeutic studies in the field. 
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Table 1. Studies on Health-Related Quality of Life in chronic inflammatory neuropathies 
(Medline search of English language articles 1966-2014). 
 
 
Authors Publication Year  Chronic 
Inflammatory 
Neuropathy 
Subtype(s) 
Study Type Number of 
Participants 
Main Outcome/Finding regarding 
HRQoL 
 
Hughes et al. [4] 2001 CIDP Therapeutic 25 No improvement on IVIg or steroids 
McCrone et al. [5] 2003 CIDP Therapeutic 25 More improvement on IVIg than on 
steroids 
Merkies et al. [2] 2002 CIDP, PDN Cross-sectional 31 Lower than in controls; 
Improvement with treatment 
Padua et al. [6] 2004 CIDP, MMN Prospective cohort 11 Improvement with IVIg 
Padua et al. [7] 2005 CIDP, MMN Prospective cohort 11 Improvement with IVIg 
Garssen et al. [8] 2004 CIDP Interventional: 
Physical Training 
4 Improvement with training 
Hughes et al. [9] 2008 CIDP Therapeutic 117 Improvement with IVIg 
Merkies et al. [10] 2009 CIDP Therapeutic 117 Improvement with IVIg  
Merkies et al. [11] 2010 CIDP Therapeutic 117 Corelation with strength, grip, 
disability 
Harbo et al. [12] 2008 CIDP Cross-sectional 14 Impairment; Correlation with 
isokinetic strength 
Harbo et al. [13] 2009 CIDP Therapeutic 11 Improvement with IVIg  
Harbo et al. [14] 2009 MMN Therapeutic 9 SCIg equivalent to IVIg 
Eftimov et al. [15] 2009 MMN Therapeutic 10 SCIg equivalent to IVIg  
Misbah et al. [16] 2011 MMN Therapeutic 8 Improvement on SCIg 
Cocito et al. [17] 2012 CIDP Therapeutic 5 SCIg equivalent to IVIg  
Cocito et al. [18] 2013 CIDP Therapeutic 10 Improved with 20% SCIg compared 
to 16% SCIg 
Braine et al. [19] 2012 MMN Therapeutic 16 SCIg equivalent to IVIg  
Nobile-Orazio et al. [20] 2012 CIDP Therapeutic 45 IV Steroids equivalent to IVIg 
Mahdi-Rogers et al. [21] 2014 CIDP, MMN, 
PDN 
Economic, HRQoL 106 Impaired compared to average 
Unrelated to treatment received 
Maxwell et al. [22] 2013 CIDP, PDN HRQoL, Social 39 Impaired compared to normal 
dos Santos et al. [23] 2014 CIDP HRQoL, cognitive 41 Impaired compared to non-matched 
normal subjects 
Niermeijer et al. [24] 2007 PDN Therapeutic 35 Improved with Cyclophosphamide + 
prednisone 
Léger et al. [25] 2013 PDN (anti-MAG 
neuropathy only) 
Therapeutic 54 Significanty improved physical 
domains with Rituximab 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
24 
 
References. 
 
1. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 
1996;334:835-840. 
 
2. Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn P for the 
Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Quality of life 
complements traditional outcome measures in immune-mediated polyneuropathies. 
Neurology 2002;59:84-91. 
 
3. Moher D, Liberati A, Tetzlaff J, Altman DG.  PRISMA Group. Preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA statement. J Clin 
Epidemiol 2009;62:1006-1012. 
 
4. Hughes RA, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van 
Doorn  P, Dalakas M, Bojar M, Swan A and the Inflammatory Neuropathy Cause and Treatment 
(INCAT) Group.  Randomized controlled trial of intravenous immunoglobulin versus oral 
prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 
2001;50:195-201. 
 
5. McCrone P, Chisholm D, Knapp M, Hughes RA, Comi C, Dalakas MC, Illa I, 
Kilindireas C, Nobile-Orazio E, Swan A, Van den Bergh P, Willison H and the 
INCAT Study Group. Cost-utility analysis of intravenous immunoglobulin and 
prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J 
Neurol 2003;10:687-694. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
25 
 
6. Padua L, Aprile I, Caliandro P, Padua R, Mazza S, Tonali P. Intravenous 
immunoglobulin treatment in autoimmune neurological disorders: pilot study on early 
effects on patients’ quality of life. J Peripher Nerv Syst 2004;9:3-6. 
 
7. Padua L, Sabatelli M, Evoli A , Pazzaglia C, Tonali P. Intravenous immunoglobulin treatment 
in Autoimmune neurological disorders-Effects on quality of life. Hum Immunol 2005;66:417-
421. 
 
8. Garssen MP, Bussmann JB, Schmitz PI, Zandbergen A, Welter TG, Merkies IS, Stam HJ, van 
Doorn PA. Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome 
and CIDP. Neurology 2004;63:2393-2395. 
 
9. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hatung H-P, 
Latov N, Merkies IS, van Doorn P; on behalf of the ICE Study Group. Intravenous 
immune globulin (10% caprylate-chromatography purified) for the treatment of 
chronic inflammatory demyelinating polyradiculoneuropathy (ICE Study): a 
randomised placebo-controlled trial. Lancet Neurology 2008;7:136-144. 
 
10. Merkies, IS, Bril V, Dalakas MC,Deng C, Donofrio P, Hanna K, Hughes RA, 
Latov N, van Doorn; on behalf of the ICE Study Group. Health-related quality of life 
improvements in CIDP with immune globulin IV 10%. The ICE Study. Neurology 
2009;72:1337-1344. 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
26 
 
11. Merkies. Hughes RA, Donofrio P, Bril V, Dalakas MC, Hanna K, Hartung H-P, 
Latov N, van Doorn P, Deng C; on behalf of the ICE Study Group. Understanding the 
consequences of chronic inflammatory demyelinating polyradiculoneuropathy from 
impairments to activity and participation restrictions and reduced quality of life: the 
ICE study. J Peripher Nerv Syst 2010;15:208-215. 
 
12. Harbo T, Andersen H, Overgaard K, Jakobsen J. Muscle performance relates to 
physical function and quality of life in long-term chronic inflammatory 
demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2008;13:208-217.  
 
13. Harbo T, Andersen H, Jakobsen J. Acute motor response following a single IVIg 
treatment course in chronic inflammatory demyelinating polyneuropathy. Muscle 
Nerve 2009;39:439-447. 
 
14. Harbo T, Andersen H, Hess A, Hansen K, Sindrup H, Jakobsen J. Subcutaneous 
versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, 
single-blinded cross-over trial. Eur J Neurol 2009;16:631-638. 
 
15. Eftimov F, Vermeulen M, de Haan R, van den Berg L, van Schaik I. 
Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher 
Nerv Syst 2009;14:93-100. 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
27 
 
16. Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, Sturzenegger 
M. A smooth transition protocol for patients with multifocal motor neuropathy going 
from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-
concept study. J Peripher Nerv Syst 2011;16:92-97. 
 
17. Cocito D, Serra G, Paolasso I,  Barila DA, Lopiano L, Cattel L. Economic and 
quality of life evaluation of different modalities of immunoglobulin therapy in chronic 
dysimmune neuropathies. J Peripher Nerv Syst 2012;17:426-428. 
 
18. Cocito D, Paolasso I, Peci E , Spagnone E, Lopiano L. Improvement of quality of 
life in patients with chronic inflammatory demyelinating polyneuropathy shifting 
from 16 to 20% subcutaneous immunoglobulins. Neurol Sci 2013;34:2061-2062. 
 
19. Braine ME, Woodall A. A comparison between intravenous and subcutaneous 
immunoglobulin. Br J Nurs 2012;8:S21-S27. 
 
20. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, 
Fazio R, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, 
Cavaletti G, Giannini F, Sabatelli M, for the IMC Trial Group. Intravenous 
immunoglobulin versus intravenous methylprednisolone for chronic inflammatory 
demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 
2012;11:493-502. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
28 
 
21. Mahdi-Rogers M, McCrone P, Hughes RA. Economic costs and quality of life in 
chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014;21:34-
39. 
 
22. Maxwell SK, Barnett C, Kokoyi S, Leung JC, Yu JJ, Bril V, Katzberg HD. 
Association of social support with quality of life in patients with polyneuropathy J 
Peripher Nerv Syst 2013;18:37-43. 
 
23. dos Santos PL, de Almeda-Ribeiro GA, Silva DM, Marques Junior W, Bareira 
AA. Chronic inflammatory demyelinating polyneuropathy: quality of life, 
sociodemographic profile and physical complaints. Arq Neuropsiquiatr 2014;72:179-
183.  
 
24. Niermeijer JM, Eurelings M, van der Linden MW, Lokhorst HM, Franssen H, 
Fischer K, Teunissen LL, van den Berg LH, Schobben F, Wokke JH, Notermans NC. 
Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy 
with IgM monoclonal gammopathy. Neurology 2007;69:50-59. 
 
25. Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, Clavelou P, Vial 
C, Steck A, Musset L, Marin B; RIMAG Study Group (France and Switzerland). 
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein 
neuropathy. Neurology 2013;80:2217-2225. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
29 
 
26. van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, 
Faber CG, Merkies IS. Rasch-built Overall Disability Scale (R-ODS) for immune-
mediated peripheral neuropathies. Neurology 2011;76:337-345. 
 
27. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related 
quality of life measure for multiple sclerosis. Qual Life Res 1995;4:187-206. 
 
28. Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for 
quality of life in epilepsy: the QOLIE-10. Epilepsia 1996;37:577-582. 
 
29. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation 
of a short measure of functioning and well being for individuals with Parkinson's 
disease. Qual Life Res 1995;4:241-248. 
 
30. Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D, 
Hobart J. Measuring quality of life in PSP: the PSP-QoL. Neurology 2006;67:39-44. 
 
31. Cavanna AE, Schrag A, Morley D, Orth M, Robertson MM, Joyce E, Critchley 
HD, Selai C. The Gilles de la Tourette syndrome-quality of life scale (GTS-QOL): 
development and validation. Neurology 2008;71:1410-1416. 
 
32. Vickrey BG, Hays RD, Beckstrand M. Development of a health-related quality of 
life measure for peripheral neuropathy. Neurorehabil Neural Repair 2000;14:93-104.  
